UnionStrong® News | Intelligence Converges in the East, Evidence Reaches New Heights — UnionStrong® Showcases Innovations at OCIN 2026 as UGuard® Becomes the World's Only AI Decision-Support Tool Back

On the banks of the Huangpu River, innovation and expertise converged in Shanghai. On October 25, 2026, the Oriental Conference of Interventional Neuroradiology 2026 (OCIN 2026), held in conjunction with the Annual Academic Meeting of the Stroke Branch of the Shanghai Medical Association, successfully concluded in Shanghai.

Since its inception in 2001, OCIN has evolved over 26 years from a regional academic gathering into one of China's largest and most influential international conferences in neurointervention. This year's event featured 78 academic forums, bringing together 863 experts from China and abroad, with 3,508 registered attendees and 33 international speakers from 18 countries. Twelve leading neurointerventional centers across China jointly presented 16 live demonstrations of advanced procedures, while the OCIN Cases × Haina Baichuan session received 232 case submissions. Seven major multicenter studies were launched or advanced, alongside the official announcement of the OCIN-ALICE international collaboration. A major highlight of the conference was the simultaneous publication of two original Chinese stroke studies, LATE-MT and MILD-MT, in the New England Journal of Medicine (NEJM).

As a pioneer in AI-powered diagnosis and treatment of neurovascular diseases, UnionStrong® actively participated in OCIN 2026, showcasing its DEEP AI for NEURO comprehensive AI solution for neurovascular care. The company was invited to witness the presentation of the two NEJM-published studies, participated in the "New Concepts & New Technologies" session and the "Future Cath Lab" roadshow, hosted a hands-on workshop, and presented its latest AI-driven innovations in neurointervention at its exhibition booth. Through in-depth exchanges with experts from around the world, UnionStrong® explored new opportunities for integrating artificial intelligence into neurointerventional care and advancing the future of intelligent neurovascular medicine.